Hikma Pharmaceuticals (HIK) Competitors

HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Does the media prefer HCM or HIK?

In the previous week, Hikma Pharmaceuticals had 1 more articles in the media than HUTCHMED. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.96 beat Hikma Pharmaceuticals' score of 0.43 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hikma Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of HCM or HIK?

36.5% of HUTCHMED shares are owned by institutional investors. Comparatively, 42.1% of Hikma Pharmaceuticals shares are owned by institutional investors. 39.0% of HUTCHMED shares are owned by insiders. Comparatively, 30.5% of Hikma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has preferable valuation and earnings, HCM or HIK?

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£610.81M	3.18	-£41.97M	-£0.04	-5,675.00
Hikma Pharmaceuticals	£3.02B	1.53	£285M	£0.65	3,212.31

Is HCM or HIK more profitable?

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.88% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	-6.87%	-5.44%	-5.90%
Hikma Pharmaceuticals	9.45%	12.88%	9.40%

Which has more risk and volatility, HCM or HIK?

HUTCHMED has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

Do analysts prefer HCM or HIK?

Hikma Pharmaceuticals has a consensus target price of GBX 2,383.33, suggesting a potential upside of 14.14%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hikma Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Does the MarketBeat Community prefer HCM or HIK?

Hikma Pharmaceuticals received 604 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.55% of users gave Hikma Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
HUTCHMED	Outperform Votes 196 78.40%	Underperform Votes 54 21.60%
Hikma Pharmaceuticals	Outperform Votes 800 70.55%	Underperform Votes 334 29.45%

Summary

Hikma Pharmaceuticals beats HUTCHMED on 13 of the 18 factors compared between the two stocks.